Di Yi Cai Jing·2025-04-28 12:27Core Insights - WuXi AppTec expects a double-digit revenue growth of 10%-15% for its continuing operations by 2025 [1][3] - The company reported a strong Q1 performance with revenue of 9.65 billion yuan, a year-on-year increase of 21%, and a net profit attributable to shareholders of 3.672 billion yuan, up 89.1% [1] - The significant increase in net profit is attributed to the sale of part of its stake in WuXi AppTec's subsidiary and investment gains from the disposal of certain businesses [1] Revenue and Profit Analysis - The adjusted non-IFRS net profit for Q1 was 2.678 billion yuan, reflecting a 40% year-on-year growth [1] - TIDES business (oligonucleotides and peptides) generated revenue of 2.24 billion yuan in Q1, marking a substantial growth of 187.6% [3] - As of March 31, 2025, the company had a backlog of 52.33 billion yuan in continuing operations, a 47.1% increase year-on-year, with TIDES backlog growing by 105.5% [3] Future Outlook - WuXi AppTec has not adjusted its 2025 full-year performance guidance despite potential impacts from new tariffs imposed by the U.S. [3] - The company anticipates overall revenue to reach between 41.5 billion yuan and 43 billion yuan in 2025 [3] - The CEO stated that the adjusted non-IFRS net profit margin is expected to further improve [3]